-0.0443  (-9.41%)
Volume (24h): 12.97M Day Range: 0.4551 - 0.5033
Market Cap: 48.96M 52W Range: 0.2200 - 1.07
May-22-20 11:00AM Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer PatientsGlobeNewswire
May-20-20 11:30AM Kitov Announces U.S. Commercial Launch of Consensi™GlobeNewswire
May-19-20 12:05PM Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting IIGlobeNewswire
May-14-20 11:10AM Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific ProgramGlobeNewswire
May-08-20 08:00PM Kitov Closes $10 Million Registered Direct OfferingGlobeNewswire
May-06-20 12:00PM Kitov Announces $10 million Registered Direct OfferingGlobeNewswire
Apr-20-20 12:05PM Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of WarrantsGlobeNewswire
Mar-17-20 12:00PM Kitov Closes $6.0 Million Public OfferingGlobeNewswire
Mar-12-20 12:15PM Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue ForecastGlobeNewswire
12:00PM Kitov Announces Pricing of $6.0 Million Public OfferingGlobeNewswire
Feb-24-20 02:00PM Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat CancersGlobeNewswire
Feb-11-20 12:00PM Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial ResultsGlobeNewswire
Feb-03-20 01:20PM Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24GlobeNewswire
Jan-24-20 01:10PM Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR InhibitorsGlobeNewswire
Jan-09-20 01:35PM Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical OfficerGlobeNewswire
Jan-08-20 12:30PM Kitov Pharma Announces Closing of FameWave AcquisitionGlobeNewswire
12:00PM Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price RuleGlobeNewswire
Oct-11-19 12:54PM Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.SGlobeNewswire
Oct-02-19 12:20PM Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its BoardGlobeNewswire
Sep-09-19 12:30PM Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug ResistanceGlobeNewswire
Sep-03-19 12:22PM Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare ConferenceGlobeNewswire
Aug-29-19 12:30PM Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care ConferenceGlobeNewswire
Aug-16-19 12:24PM Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition DealGlobeNewswire
Aug-14-19 12:20PM Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities AuthorityGlobeNewswire
Aug-08-19 12:20PM Kitov Pharma Reports First Half 2019 Financial Results and Provides Business UpdateGlobeNewswire
Jul-12-19 09:11PM Kitov Receives Nasdaq Notification Regarding Minimum Bid RequirementsGlobeNewswire
Jun-27-19 11:30AM Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck CancersGlobeNewswire
May-10-19 01:20PM Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™GlobeNewswire
May-09-19 12:30PM Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED ConferenceGlobeNewswire
May-02-19 08:45PM Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul WaymackGlobeNewswire
Apr-12-19 12:28PM Kitov Announces Key Milestone in FameWave AcquisitionGlobeNewswire
11:49AM FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)GlobeNewswire
Mar-18-19 12:20PM Potential Milestones Coming for Kitov Pharma and Product Commercialization PlansACCESSWIRE
Mar-14-19 06:30PM These Four Healthcare Stocks Could Test March HighsACCESSWIRE
01:09PM Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology CompanyGlobeNewswire
Feb-07-19 01:06PM Kitov Pharma Reports Year End 2018 Financial Results and Provides Business UpdateGlobeNewswire
Jan-21-19 01:30PM A Biotech Play You Can't Afford To MissACCESSWIRE
Jan-18-19 09:30PM Kitov Closes $6 Million Registered Direct OfferingGlobeNewswire
03:00PM Small Caps Soaring Off of BottomsACCESSWIRE
Jan-18-19 02:11PM Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNYZacks
Jan-16-19 09:26PM Kitov Pharma's Stock Up on Anti-Cancer Candidate FindingsZacks
06:35PM Kitov Announces Pricing of $6 Million Registered Direct OfferingGlobeNewswire
Jan-16-19 02:26PM 4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19)ACCESSWIRE
Jan-15-19 07:01PM Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug FindingsInvestorPlace
01:41PM New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer EffectGlobeNewswire
Jan-07-19 05:25PM 4 Healthcare Stocks Making Moves On Monday (1/7/19)ACCESSWIRE
Jan-03-19 01:35PM 4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)ACCESSWIRE
12:19PM Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis PharmaceuticalsGlobeNewswire
Jul-17-18 11:35AM Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech StocksACCESSWIRE
Jun-01-18 12:20PM Today’s Research Reports on Stocks to Watch: Kitov Pharma and Clearside BiomedicalACCESSWIRE
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)